(NASDAQ: TBPH) Theravance Biopharma's forecast annual revenue growth rate of 19.39% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Theravance Biopharma's revenue in 2025 is $65,266,000.On average, 3 Wall Street analysts forecast TBPH's revenue for 2025 to be $4,801,777,916, with the lowest TBPH revenue forecast at $4,800,127,872, and the highest TBPH revenue forecast at $4,805,128,005. On average, 3 Wall Street analysts forecast TBPH's revenue for 2026 to be $4,179,411,337, with the lowest TBPH revenue forecast at $4,100,109,224, and the highest TBPH revenue forecast at $4,285,614,166.
In 2027, TBPH is forecast to generate $5,952,808,579 in revenue, with the lowest revenue forecast at $5,700,151,848 and the highest revenue forecast at $6,420,671,042.